



## **Bolt Biotherapeutics to Present at 2020 Jefferies Virtual Healthcare Conference**

**Redwood City, Calif., May 27, 2020** –Bolt Biotherapeutics, Inc., a private clinical-stage biotechnology company developing its Immune-Stimulating Antibody Conjugate (ISAC) platform technology to harness the power of the immune system to treat cancer, today announced that Randall Schatzmann, Ph.D., chief executive officer of Bolt, will present a company overview at the 2020 Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:00 PM ET.

### **About Bolt Biotherapeutics, Inc.**

Bolt Biotherapeutics, based in the San Francisco Bay Area, is a private clinical-stage biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISACs), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies while also developing immunological memory, which may lead to more durable clinical responses for patients. Boltbody™ technology is applicable to a broad spectrum of antibodies targeting tumor antigens expressed on all types of cancer, including patients who are refractory to the current generation of checkpoint inhibitors. The company was founded by Dr. Ed Engleman, and its platform is based on technology exclusively licensed from Stanford University. The company is financed by world-class investors including Novo Holdings, Pivotal bioVenture Partners, Vivo Capital and Nan Fung Life Sciences. For more information about Bolt Biotherapeutics, please visit [www.boltbio.com](http://www.boltbio.com).

### **Media Contacts:**

Maggie Beller or David Schull

Russo Partners, LLC

646-942-5631

[maggie.beller@russopartnersllc.com](mailto:maggie.beller@russopartnersllc.com)

[david.schull@russopartnersllc.com](mailto:david.schull@russopartnersllc.com)

### **Investor Relations Contact:**

Sarah McCabe

Stern Investor Relations, Inc.

212-362-1200

[sarah.mccabe@sternir.com](mailto:sarah.mccabe@sternir.com)